Abilify receives FDA approval for expeanded indication in treating bipolar disorder
- Bristol-Myers Squibb Co. and Japanese partner Otsuka Pharmaceutical Co. said Thursday that the FDA granted approval for Abilify to aid with the treatment of bipolar disorder. Abilify is now indicated as a secondary therapy alongside lithium and valproate for treating bipolar episodes in adults.
Abilify was already approved alone for the treatment of certain kinds of bipolar disorder in adults and adolescents.
Shares of Bristol Myers Squibb Co. rose 21 cents Friday to $23 in after-hours trading, following an earlier close at $22.79.
Many health professionals were of course already using Abilify in this manner, but it is always a sigh of relief when the FDA gives their stamp of approval.
Any thoughts or comments on your clinical experience when using Abilify?
Abilify was already approved alone for the treatment of certain kinds of bipolar disorder in adults and adolescents.
Shares of Bristol Myers Squibb Co. rose 21 cents Friday to $23 in after-hours trading, following an earlier close at $22.79.
Many health professionals were of course already using Abilify in this manner, but it is always a sigh of relief when the FDA gives their stamp of approval.
Any thoughts or comments on your clinical experience when using Abilify?
About
Jobs and Colleagues Search
Networking Tools
Direct chat
Birthdays
There are no birthdays today
Badge
© 2009 Created by Raymond van den Bel on Ning. Create Your Own Social Network
